[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dnmt3a-gene-mutation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dnmt3a-gene-mutation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100607452","metformin-inhibits-dnmt3a-clonal-hematopoiesis-in-acute-leukemia-100607452",false,"NCT07188740","Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia","Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia: A Single-Arm Clinical Study","Inclusion Criteria:\n\n* Patients diagnosed with acute leukemia based on bone marrow morphology, immunology, and genetics, per WHO 2022 or ICC criteria.\n* Patients in complete remission follow-up phase with DNMT3A R882 mutation clonal hematopoiesis, VAF ≥5%.\n* Age ≥14 years, any gender\n* Laboratory requirements (within 7 days before treatment):\n\n  * Total bilirubin ≤1.5 × upper limit of normal (ULN) for age.\n  * AST and ALT ≤2.5 × ULN for age.\n  * Serum creatinine \\\u003C2 × ULN for age.\n  * Cardiac enzymes \\\u003C2 × ULN for age.\n  * Ejection fraction within normal range by echocardiogram (ECHO).\n* Signed informed consent: By patient (≥18 years) or legal guardian\u002Frelative (\\\u003C18 years or if beneficial for condition).\n\nExclusion Criteria:\n\n* Patients with diabetes receiving other medications\n* Known allergy to metformin\n* Deemed unsuitable by investigator","ALL","14 Years",{"count":19,"type":20},32,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a prospective, single-arm clinical study evaluating the efficacy and safety of metformin in inhibiting DNMT3A R882-driven clonal hematopoiesis (CH) in patients with acute leukemia (AL) who are in remission and under follow-up. Patients with DNMT3A R882 mutation (VAF ≥5%) will receive oral metformin for 6 months, with dosage gradually increased to 2000 mg\u002Fday. The primary endpoint is the proportion of patients with effective decline in DNMT3A R882 mutation VAF at 6 months. Secondary endpoints include VAF decline at 3 months, relapse-free survival (RFS) at 6 and 12 months, overall survival (OS), cumulative incidence of relapse (CIR), cumulative remission-phase mortality, and adverse event rates. Planned enrollment: 32 participants.",[26],"DNMT3A Gene Mutation",[28,29,30,31],"CHIP","acute leukemia","Metformin","DNMT3A","RECRUITING","2026-08-05",{"date":35,"type":36},"2026-08-10","ACTUAL",{"date":38,"type":20},"2026-08-30",{"date":40,"type":20},"2029-08-30",{"name":42,"class":43},"Institute of Hematology & Blood Diseases Hospital, China","OTHER"]